Talpaz M - Search Results

1

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.

Shah NP, Talpaz M, Deininger MW, Mauro MJ, Flinn IW, Bixby D, Lustgarten S, Gozgit JM, Clackson T, Turner CD, Haluska FG, Kantarjian H, Cortes JE. Shah NP, et al. Among authors: talpaz m. Br J Haematol. 2013 Aug;162(4):548-52. doi: 10.1111/bjh.12382. Epub 2013 May 21. Br J Haematol. 2013. PMID: 23691988 Free PMC article. Clinical Trial. No abstract available.

2

Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation.

Lee M, Khouri I, Champlin R, Kantarjian H, Talpaz M, Trujillo J, Freireich E, Deisseroth A, Stass S. Lee M, et al. Among authors: talpaz m. Br J Haematol. 1992 Dec;82(4):708-14. doi: 10.1111/j.1365-2141.1992.tb06948.x. Br J Haematol. 1992. PMID: 1482658

3

Activation of class I HLA expression by TNF-alpha and gamma-interferon is mediated through protein kinase C-dependent pathway in CML cell lines.

Seong D, Sims S, Johnson E, Lyding J, Lopez A, Garovoy M, Talpaz M, Kantarjian H, Lopez-Berestein G, Reading C, et al. Seong D, et al. Among authors: talpaz m. Br J Haematol. 1991 Jul;78(3):359-67. doi: 10.1111/j.1365-2141.1991.tb04449.x. Br J Haematol. 1991. PMID: 1908310

4

Interferon alpha in the therapy of CML.

Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Talpaz M, et al. Br J Haematol. 1991 Oct;79 Suppl 1:38-41. doi: 10.1111/j.1365-2141.1991.tb08117.x. Br J Haematol. 1991. PMID: 1931707

5

Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes.

Estey EH, Kurzrock R, Talpaz M, McCredie KB, O'Brien S, Kantarjian HM, Keating MJ, Deisseroth AB, Gutterman JU. Estey EH, et al. Among authors: talpaz m. Br J Haematol. 1991 Mar;77(3):291-5. doi: 10.1111/j.1365-2141.1991.tb08573.x. Br J Haematol. 1991. PMID: 2012752

6

Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia.

Kantarjian HM, Kurzrock R, Talpaz M. Kantarjian HM, et al. Among authors: talpaz m. Hematol Oncol Clin North Am. 1990 Apr;4(2):389-404. Hematol Oncol Clin North Am. 1990. PMID: 2182598 Review.

7

Biologic agents for the management of hematological disorders: chronic myeloid leukemia.

McCredie KB, Talpaz M, Kantarjian H, Rosenblum M, Keating M, Gutterman J. McCredie KB, et al. Among authors: talpaz m. Haematol Blood Transfus. 1987;31:120-2. doi: 10.1007/978-3-642-72624-8_25. Haematol Blood Transfus. 1987. PMID: 2450815 No abstract available.

8

Therapy of chronic myelogenous leukaemia with interferons.

Talpaz M, Kurzrock R, Kantarjian H, Gutterman J. Talpaz M, et al. Cancer Surv. 1989;8(4):793-8. Cancer Surv. 1989. PMID: 2701727 Review.

9

Recent advances in the therapy of chronic myelogenous leukemia.

Talpaz M, Kurzrock R, Kantarjian HM, Gutterman JU. Talpaz M, et al. Important Adv Oncol. 1988:297-321. Important Adv Oncol. 1988. PMID: 3042607 Review. No abstract available.

10

Definition of the accelerated phase of chronic myelogenous leukemia.

Kantarjian HM, Talpaz M. Kantarjian HM, et al. Among authors: talpaz m. J Clin Oncol. 1988 Jan;6(1):180-2. doi: 10.1200/JCO.1988.6.1.180. J Clin Oncol. 1988. PMID: 3422090 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

604 results

Search Page

Filters